Stephenson Harwood LLP has advised Oxford Biomedica on the deal. Oxford Biomedica started a collaboration with biopharmaceutical company PhoreMost, to develop next-generation CAR-T cell therapies. CAR-T…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
